Biogen ALS Drug Showed No Benefit, O'Neill Says

Jan. 3 (Bloomberg) -- Gilmore O’Neill, vice president of clinical development at Biogen Idec Inc., talks with Bloomberg's Meg Tirrell about the company's announcement that its experimental drug for amyotrophic lateral sclerosis failed to help patients in a clinical trial. Biogen sank 1.4 percent to $147.86 at 4 p.m. New York time after saying it will end development of the medicine for ALS, also known as Lou Gehrig’s disease. (Source: Bloomberg)

ESPN Drags Down Disney Shares
22:34 - Walt Disney reported record sales and earnings in the first quarter, thanks to the latest instalment in the "Star Wars" film series, but saw sagging profits at its ESPN network. Bloomberg Intelligence's Paul Sweeney and Bloomberg's Cory Johnson break down the results on "Bloomberg ‹GO›." (Source: Bloomberg)
  • Disney Tops Estimates: Bloomberg West (Full Show 02/09)
  • Can Markets Weather a Perfect Storm of Volatility?
  • What Are the Biggest Economic and Market Concerns?